Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted immunoconjugate of N-acetyl-gamma-calicheamicin dimethyl hydrazide [CalichDMH], a potent DNA-binding cytotoxic antitumor antibiotic) is a clinically validated therapeutic option for patients with acute myeloid leukemia (AML). Here, we describe the preclinical profile of another immunoconjugate of CalichDMH, CMC-544, targeted to CD22 expressed by B-lymphoid malignancies. CMC-544 comprises a humanized IgG4 anti-CD22 monoclonal antibody (mAb), G5/44, covalently linked to CalichDMH via an acid-labile 4-(4'-acetylphenoxy) butanoic acid (AcBut) linker. Both CMC-544 and unconjugated G5/44 bound human CD22 with subnanomolar affinity. CMC-544, but not unconjugated G5/44, exerted potent cytotoxicity against CD22+ B-cell lymphoma (BCL) cell lines (inhibitory concentration of 50%: 6-600 pM CalichDMH). CMC-544 caused a potent inhibition of growth of small but established BCL xenografts leading to cures (therapeutic index > 10). CMC-544 prevented the establishment of BCL xenografts and also caused regression of large BCLs (> 1.5 g tumor mass). In contrast, unconjugated CalichDMH, unconjugated G5/44, and an isotype-matched control conjugate, CMA-676, were ineffective against these BCL xenografts. Thus, CD22-targeted delivery of CalichDMH is a potent and effective preclinical therapeutic strategy for BCLs. The strong antitumor profile of CMC-544 supports its clinical evaluation as a treatment option for B-lymphoid malignancies.

[1]  M. Walker,et al.  Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. , 1999, Pharmacology & therapeutics.

[2]  P. Frost,et al.  Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. , 2003, Current opinion in pharmacology.

[3]  M. Gibaldi,et al.  Pharmacokinetics, Second Edition , 1982 .

[4]  Kreitman Rj.  Toxin-labeled monoclonal antibodies. , 2001 .

[5]  R. Kreitman.  Recombinant toxins for the treatment of cancer. , 2003, Current opinion in molecular therapeutics.

[6]  I. Bernstein,et al.  Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) , 2002, Leukemia.

[7]  J. Leonard,et al.  Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). , 2002, Seminars in oncology.

[8]  A. Varki,et al.  Siglecs, sialic acids and innate immunity. , 2001, Trends in immunology.

[9]  M. J. Mattes,et al.  Processing of antibodies bound to B-cell lymphomas and other hematological malignancies. , 1996, Cancer research.

[10]  P. Crocker,et al.  New Functions for the Sialic Acid‐Binding Adhesion Molecule CD22, a Member of the Growing Family of Siglecs , 2001, Scandinavian journal of immunology.

[11]  W. Wilson,et al.  Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. , 2001, The New England journal of medicine.

[12]  R. Kreitman,et al.  Toxin-labeled monoclonal antibodies. , 2001, Current pharmaceutical biotechnology.

[13]  R. Wallace,et al.  Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. , 1993, Cancer research.

[14]  Irwin Hollander,et al.  Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. , 2002, Bioconjugate chemistry.

[15]  D. Newton,et al.  Specifically Targeting the CD22 Receptor of Human B-cell Lymphomas with RNA Damaging Agents: A New Generation of Therapeutics , 2002, Leukemia & lymphoma.

[16]  I. Bernstein,et al.  An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. , 2002, Bioconjugate chemistry.

[17]  G. Ellestad,et al.  Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. , 1988, Science.

[18]  X. H. Chen,et al.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  I. Bernstein,et al.  Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties , 1989, The Journal of experimental medicine.

[20]  I. Bernstein,et al.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Sausville,et al.  The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  M. Berger,et al.  Licensure of Gemtuzumab Ozogamicin for the Treatment of Selected Patients 60 Years of Age or Older with Acute Myeloid Leukemia in First Relapse , 2002, Investigational New Drugs.

[23]  O. Press,et al.  Constitutive endocytosis and degradation of CD22 by human B cells. , 1995, Journal of immunology.

[24]  M. Berger,et al.  Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse , 2001, Journal of clinical pharmacology.

[25]  P. Trail,et al.  Monoclonal antibody drug conjugates in the treatment of cancer. , 1999, Current opinion in immunology.

[26]  J. Leonard,et al.  Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). , 2002, Seminars in oncology.

[27]  Ira Pastan,et al.  Immunotoxins in cancer therapy. , 1999, Current opinion in investigational drugs.

[28]  R. Gressin,et al.  In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. , 2003, Blood.

[29]  M. Siegel,et al.  Calicheamicins, a novel family of antitumor antibiotics. 4. Structure elucidation of calicheamicins .beta.1Br, .gamma.1Br, .alpha.2I, .alpha.3I, .beta.1I, .gamma.1I, and .delta.1I , 1992 .

[30]  J. Thorson,et al.  Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. , 2000, Current pharmaceutical design.

[31]  S. Sato,et al.  CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. , 1997, Annual review of immunology.

[32]  L. Santos‐Argumedo,et al.  Expression and Function of CD22, a B‐cell Restricted Molecule * , 2002, Scandinavian journal of immunology.

[33]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.